WO2024260434 - COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR)
National phase entry:
Publication Number
WO/2024/260434
Publication Date
26.12.2024
International Application No.
PCT/CN2024/100524
International Filing Date
21.06.2024
Title **
[English]
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR)
[French]
COMPOSITIONS ET PROCÉDÉS POUR INHIBER L'EXPRESSION DE LA 3-HYDROXY-3-MÉTHYLGLUTARYL-COA RÉDUCTASE (HMGCR)
Applicants **
SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.
J2026, Room 1_203, 337 Shahe Road, Jiangqiao Town
Jiading District, Shanghai 201803, CN
Inventors
SHU, Dongxu
Room 201, No. 24, Lane 535, Qingnian Road, Qiuai Town, Yinzhou District
Ningbo, Zhejiang 315100, CN
SHAO, Pengcheng Patrick
631 Addison Way, Warrington Township
Pennsylvania 18976, US
XIA, Shiwei
Minqiang VillageLishan Town, Fuyang District
Hangzhou, Zhejiang 311400, CN
Priority Data
PCT/CN2023/101548
21.06.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3908 | |
| EPO | Filing, Examination | 39529 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 20210 |
Total: 64808 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Compositions and methods useful to reduce expression of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene and for treatment of HMGCR-associated diseases and conditions. HMGCR dsRNA agents, HMGCR antisense polynucleotide agents, compositions comprising HMGCR dsRNA agents, and compositions comprising HMGCR antisense polynucleotide agents that can be used to reduce HMGCR expression in cells and subjects.[French]
L'invention concerne des compositions et des procédés utiles pour réduire l'expression du gène 3-hydroxy-3-méthylglutaryl-CoA réductase (HMGCR) et pour le traitement de maladies et d'états pathologiques associés à HMGCR. L'invention concerne également des agents ARNdb HMGCR, des agents polynucléotidiques antisens HMGCR, des compositions comprenant des agents ARNdb HMGCR, et des compositions comprenant des agents polynucléotidiques antisens HMGCR qui peuvent être utilisés pour réduire l'expression de HMGCR dans des cellules et chez des sujets.